IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
-5.26%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$329M
AUM Growth
-$20.7M
(-5.9%)
Cap. Flow
+$40.1M
Cap. Flow
% of AUM
12.19%
Top 10 Holdings %
Top 10 Hldgs %
37.77%
Holding
184
New
15
Increased
124
Reduced
11
Closed
9
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$8.27M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$7.11M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$6.52M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$6.34M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$5.94M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$11.3M |
| 2 |
Biogen
BIIB
|
$6M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$5.89M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$3.95M |
| 5 |
iShares Biotechnology ETF
IBB
|
$3.67M |
Sector Composition
| 1 | Healthcare | 98.75% |
| 2 | Consumer Staples | 0.62% |
| 3 | Technology | 0.36% |
| 4 | Financials | 0.23% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioMarin Pharmaceuticals
BMRN
$10.9B
| $3.86M | 0.51% |
+50,000
| New | +$3.86M |
|
|
CMRX
27
DELISTED
Chimerix, Inc.
CMRX
| $3.85M | 0.51% |
841,203
+45,793
| +6% | +$210K |
|
|
WHWK
28
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $3.54M | 0.47% |
208,368
+11,960
| +6% | +$203K |
|
|
INBX
29
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $3.52M | 0.46% |
157,842
+7,992
| +5% | +$178K |
|
30
Intellia Therapeutics
NTLA
$1.24B
| $3.45M | 0.45% |
+47,408
| New | +$3.45M |
|
|
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.85M | 0.37% |
+86,905
| New | +$2.85M |
|
|
AYLA
32
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $2.82M | 0.37% |
708,383
+39,112
| +6% | +$156K |
|
|
STSA
33
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $2.48M | 0.33% |
653,448
+24,064
| +4% | +$91.4K |
|
34
X4 Pharmaceuticals
XFOR
$81.7M
| $2.4M | 0.32% |
45,734
-29,749
| -39% | -$1.56M |
|
|
PRDS
35
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $2.34M | 0.31% |
323,934
-76,066
| -19% | -$549K |
|
36
Ovid Therapeutics
OVID
$92.4M
| $2.32M | 0.3% |
738,372
+33,290
| +5% | +$105K |
|
37
Savara
SVRA
$598M
| $2.13M | 0.28% |
1,622,552
+82,861
| +5% | +$109K |
|
38
Kymera Therapeutics
KYMR
$2.92B
| $2.12M | 0.28% |
+50,000
| New | +$2.12M |
|
39
Wave Life Sciences
WVE
$1.26B
| $2.1M | 0.28% |
1,048,039
+54,558
| +5% | +$109K |
|
40
Cabaletta Bio
CABA
$139M
| $2.07M | 0.27% |
1,020,070
+49,672
| +5% | +$101K |
|
|
CNTB
41
Connect Biopharma Holdings Limited Ordinary Shares
CNTB
$103M
| $2.05M | 0.27% |
677,859
+415,622
| +158% | +$1.26M |
|
42
Clene
CLNN
$57.5M
| $2.03M | 0.27% |
25,714
+1,248
| +5% | +$98.3K |
|
43
Liquidia Corp
LQDA
$2.46B
| $1.75M | 0.23% |
243,904
-81,541
| -25% | -$585K |
|
|
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.73M | 0.23% |
49,997
-114,085
| -70% | -$3.95M |
|
45
Lyra Therapeutics
LYRA
$11.6M
| $1.7M | 0.22% |
8,447
+556
| +7% | +$112K |
|
46
Aldeyra Therapeutics
ALDX
$343M
| $1.67M | 0.22% |
+375,000
| New | +$1.67M |
|
|
FNCH
47
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $1.66M | 0.22% |
11,017
+493
| +5% | +$74.4K |
|
48
Viking Therapeutics
VKTX
$2.94B
| $1.6M | 0.21% |
532,429
+31,787
| +6% | +$95.3K |
|
|
CLVS
49
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.56M | 0.21% |
772,339
-340,330
| -31% | -$688K |
|
|
AUTL
50
Autolus Therapeutics
AUTL
$381M
| $1.55M | 0.2% |
372,217
-172,602
| -32% | -$720K |
|